<DOC>
	<DOC>NCT01105325</DOC>
	<brief_summary>To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance over 3 months with the two principal treatments of the prescription (a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®), using an electronic measure system ("intelligent blister" pack®);</brief_summary>
	<brief_title>Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®clopidogrel) Patient giving his/her oral consent to participate in the study. Patient not previously treated by a lipidlowering drug. Patient with a known history of coronary heart disease. Patient whose treatment on discharge comprises only one of the two study treatments Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>treatment compliance</keyword>
	<keyword>cardiac intensive care unit</keyword>
	<keyword>secondary prevention</keyword>
	<keyword>cardiac intensive care unit (CIC)</keyword>
	<keyword>compliance</keyword>
	<keyword>intensive care</keyword>
</DOC>